ACE2 and inflammatory bowel disease: Beyond ACE2 expression, the use of immunosuppressive medications in IBD treatment further complicates this relationship, as patients on corticosteroids or 5-aminosalicylic acid (5-ASA) exhibit higher rates of hospitalization, Intensive Care Unit (ICU) admission, and death, suggesting that severe inflammation and immune dysregulation, rather than IBD itself, may drive worse outcomes.